Ravulizumab (Ultomiris®) approved for the treatment of PNH!
On July 2nd, 2019, ravulizumab (Ultomiris®) was approved in the EU for the treatment of adult patients with PNH. Patients are suitable for treatment with haemolysis and at least one other clinical symptom that indicates high disease activity, as well as clinically stable patients who have received eculizumab in the previous 6 months.
Ravulizumab is a further development of the currently only available PNH drug eculizumab (Soliris®) and only needs to be administered as an infusion every 8 weeks instead of every 2 weeks as before. Studies have shown that ravulizumab is not inferior to its “predecessor” eculizumab in terms of efficacy and safety.